2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.
Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.
From a business standpoint, a new molecular lab has been created, Pecora explains. Secondly, a license has been obtained for RCCA to be its own oral dispensing pharmacy. Though this profits cancer centers, Pecora says this will allow for more cost control, lower costs of services, and increase convenience and safety for patients.
The oral dispensing pharmacy allows for the ability to track patients’ compliance to medication as well as adverse events associated with medications. With the creation of the molecular lab, the services are provided below market price, compared with other reference laboratories.
Related Content: